{
  "id": "b784849c79446f43",
  "title": "Imugene reports strong azer - cel data as clinical and regulatory momentum builds",
  "description": "Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) reported further positive clinical results during the December 2025 quarter, with its azer-cel Phase 1b trial...",
  "content": "![logo-loader](https://cdn.proactiveinvestors.com/assets/svg/loader-logo-rotate.svg)\n\n![](https://cdn.proactiveinvestors.com/assets/img/logo.png)\n\n[Health](https://www.proactiveinvestors.com/health) [Pharma & Biotech](https://www.proactiveinvestors.com/pharma)\n\nWritten by:\n\n[**Jonathan Jackson**](https://www.proactiveinvestors.com/teams/details/398/Jonathan-Jackson)\n\nThis record is published on behalf of Imugene Ltd, a paid client of Proactive\n\n[About this content](https://www.proactiveinvestors.com/companies/news/1086533/imugene-reports-strong-azer-cel-data-as-clinical-and-regulatory-momentum-builds-1086533.html#) [Disclaimer\\\\\n\\\\\nNo investment advice](https://www.proactiveinvestors.com/companies/news/1086533/imugene-reports-strong-azer-cel-data-as-clinical-and-regulatory-momentum-builds-1086533.html#)\n\nShare article\n\n[Imugene Ltd](https://www.proactiveinvestors.com/ASX:IMU/Imugene-Ltd/)\n\n(\n\nASX:IMUOTC:IUGNF\n\n)\n\n[View Price & Profile](https://www.proactiveinvestors.com/ASX:IMU/Imugene-Ltd/)\n\n# Imugene reports strong azer-cel data as clinical and regulatory momentum builds\n\nPublished: 20:38 29 Jan 2026 EST\n\n\n![Imugene Ltd - Imugene reports strong azer-cel data as clinical and regulatory momentum builds](https://cdn.proactiveinvestors.com/eyJidWNrZXQiOiJwYS1jZG4iLCJrZXkiOiJ1cGxvYWRcL05ld3NcL0ltYWdlXC8yMDI2XzAxXC9wb3NpdGl2ZWZlZWRiYWNrLmpwZyIsImVkaXRzIjp7InJlc2l6ZSI6eyJ3aWR0aCI6MTI4MCwiaGVpZ2h0Ijo3MjAsImZpdCI6ImNvdmVyIn19fQ==)\n\n[Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA)](https://www.proactiveinvestors.com/ASX:IMU/Imugene-Ltd/) reported further positive clinical results during the December 2025 quarter, with its azer-cel Phase 1b trial achieving an Overall Response Rate of 82% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).\n\nOf the 17 evaluable patients treated, 14 responded to therapy, including seven\u00a0complete responses and seven\u00a0partial responses. The company said responses were rapid, with best responses typically observed within one to",
  "source": "proactiveinvestors.com",
  "source_url": "https://www.proactiveinvestors.com/companies/news/1086533/imugene-reports-strong-azer-cel-data-as-clinical-and-regulatory-momentum-builds-1086533.html",
  "published_at": "20260130T050000Z",
  "fetched_at": "2026-01-31T00:26:46.418942+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "regulatory"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.proactiveinvestors.com/companies/news/1086533/imugene-reports-strong-azer-cel-data-as-clinical-and-regulatory-momentum-builds-1086533.html",
    "url_mobile": "",
    "title": "Imugene reports strong azer - cel data as clinical and regulatory momentum builds",
    "seendate": "20260130T050000Z",
    "socialimage": "https://cdn.proactiveinvestors.com/eyJidWNrZXQiOiJwYS1jZG4iLCJrZXkiOiJ1cGxvYWRcL05ld3NcL0ltYWdlXC8yMDI2XzAxXC9wb3NpdGl2ZWZlZWRiYWNrLmpwZyIsImVkaXRzIjp7InJlc2l6ZSI6eyJ3aWR0aCI6MTIwMCwiaGVpZ2h0Ijo2MzAsImZpdCI6ImNvdmVyIn19fQ==",
    "domain": "proactiveinvestors.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}